Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced a new five-year roadmap, "Alnylam 2030," on Sunday, outlining the company’s focus on scaling its operations.

The strategy builds on the company's history of setting and meeting long-term goals, following the completion of its prior P5x25 plan. Management said Alnylam has met or exceeded all previous five-year objectives, setting the stage for its next phase of expansion.

At the core of Alnylam 2030 is a push to establish durable global leadership in transthyretin, or TTR, diseases. The company aims to lead the TTR market in revenue by 2030 and cumulatively over the next five years.

A key component of that plan is the ...